FOI 6507 – Q2

|  |  |
| --- | --- |
| **Treatment** | **Patients in last 3 months** |
| Bortezomib [Velcade] and Dexamethasone |  |
| Bortezomib [Velcade], Thalidomide and Dexamethasone [known as VTD] |  |
| Bortezomib [Velcade], Cyclophosphamide/Melphalan and Dexamethasone/Prednisolone [known as VCD or VMP] |  |
| Lenalidomide [Revlimid] monotherapy |  |
| Lenalidomide [Revlimid] and Dexamethasone |  |
| Lenalidomide [Revlimid], Bortezomib [Velcade] and Dexamethasone |  |
| Lenalidomide [Revlimid], Melphalan and Prednisolone |  |
| Thalidomide, Cyclophosphamide/Melphalan, and Dexamethasone/Prednisolone [known as MPT or CTD] |  |
| Bortezomib [Velcade] monotherapy |  |
| Carfilzomib [Kyprolis] and Dexamethasone |  |
| Carfilzomib [Kyprolis], Lenalidomide [Revlimid], and Dexamethasone [known as KRD] |  |
| Daratumumab [Darzalex], Velcade [Bortezomib] and Dexamethasone [known as DVD] |  |
| Daratumumab [Darzalex], Velcade [Botezomib], Thalidomide and Dexamethasone [known as Dara-VTd] |  |
| Daratumumab [Darzalex], Lenalidomide [Revlimid] and Dexamethasone |  |
| Daratumumab [Darzalex], Pomalidomide [Imnovid] and Dexamethasone (DaraPd) |  |
| Daratumumab [Darzalex] monotherapy |  |
| Isatuximab [Sarclisa], Pomalidomide [Imnovid] and Dexamethasone [known as IsaPd] |  |
| Isatuximab [Sarclisa], Carfilzomib [Kyprolis] and Dexamethasone [known as IsaKd] |  |
| Ixazomib [Ninlaro], Lenalidomide [Revlimid] and Dexamethasone [known as IRD] |  |
| Pomalidomide [Imnovid] and Dexamethasone |  |
| Panobinostat [Farydak], Bortezomib [Velcade] and Dexamethasone |  |
| Any other systemic anti-cancer treatment |  |